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Efficient approaches for the precise genetic engineering 
of human pluripotent stem cells (hPSCs) can enhance 
both basic and applied stem cell research. Adeno- 
associated virus (AAV) vectors are of particular interest for 
their capacity to mediate efficient gene delivery to and 
gene targeting in various cells. However, natural AAV sero-
types offer only modest transduction of human embry-
onic and induced pluripotent stem cells (hESCs and 
hiPSCs), which limits their utility for efficiently manipu-
lating the hPSC genome. Directed evolution is a powerful 
means to generate viral vectors with novel capabilities, 
and we have applied this approach to create a novel AAV 
variant with high gene delivery efficiencies (~50%) to 
hPSCs, which are importantly accompanied by a con-
siderable increase in gene-targeting frequencies, up to 
0.12%. While this level is likely sufficient for numerous 
applications, we also show that the gene-targeting effi-
ciency mediated by an evolved AAV variant can be further 
enhanced (>1%) in the presence of targeted double- 
stranded breaks (DSBs) generated by the co-delivery of 
artificial zinc finger nucleases (ZFNs). Thus, this study 
demonstrates that under appropriate selective pressures, 
AAV vectors can be created to mediate efficient gene 
targeting in hPSCs, alone or in the presence of ZFN- 
mediated double-stranded DNA breaks.
Received 26 May 2011; accepted 27 October 2011; published online  
22 November 2011. doi:10.1038/mt.2011.255
IntroductIon
The capacity to mediate high efficiency gene delivery to human 
pluripotent stem cells (hPSCs) has numerous applications, rang-
ing from the study of specific genes in stem cell self-renewal and 
differentiation to the directed differentiation of stem cells into 
specific lineages for therapeutic application. Furthermore, pre-
cise manipulation of the human stem cell genome using gene- 
targeting techniques that exploit the natural ability of cells to 
perform homologous recombination (HR) has broad applications 
and implications, including safe harbor integration of genes for 
basic or therapeutic application, creating in vitro models for investi-
gating human development and disease, and high-throughput drug 
discovery and toxicity studies.1,2 However, while gene delivery and 
gene targeting are well established for various mammalian somatic 
cells,3 a readily generalized approach for efficient gene expression 
and gene targeting in hPSCs requires further development.
Current methods to deliver genes to hPSCs range from viral 
vectors to plasmid-based transient gene expression. Lentiviral 
vectors—which are highly efficient and result in long-term gene 
expression—have been extensively employed in numerous studies 
in human stem cells.4 However, transient expression is desirable in 
some cases, such as for the temporary overexpression of regulatory 
signals to manipulate stem cell fate decisions.5,6 Also, vector integra-
tion into the genome can risk insertional mutagenesis, a potential 
concern for downstream clinical application.4 As an alternative, 
electroporation can be used to achieve transient gene expression, 
though this method can suffer from low transfection efficiencies and 
moderate toxicity in human stem cells.7 In addition to gene deliv-
ery, there is a need to develop efficient gene-targeting methods that 
rely on HR to introduce permanent and sequence-specific genome 
modifications in hPSCs. Several impressive studies have demon-
strated successful gene targeting in hPSCs, though the initial rates 
reported using conventional methodologies are low (10−7–10−5 cor-
rectly targeted cells for every original cell in the population), which 
necessitates the use of positive and negative selection to improve the 
overall efficiency and specificity of the process.8,9
Recently, several approaches have been utlized to improve 
gene targeting in hPSCs, including the introduction of double-
stranded breaks (DSBs) into the cellular genome by engineered 
nucleases.10–14 Such breaks stimulate the cellular DNA repair 
machinery and thereby greatly enhance the rate of homologous 
recombination with a donor DNA.15 For example, Zou et al. found 
that cotransfection of plasmids containing the donor DNA and 
zinc finger nucleases (ZFNs) significantly increased gene tar-
geting in hPSCs up to a frequency of 0.24% (~1 targeted cell in 
The first two authors contributed equally to this work.
Correspondence: David V Schaffer, Department of Chemical and Biomolecular Engineering, University of California, Berkeley, 274 Stanley Hall, Berkeley, 
California 94720-1462, USA. E-mail: schaffer@berkeley.edu
Directed Evolution of Adeno-associated Virus  
for Enhanced Gene Delivery and Gene Targeting  
in Human Pluripotent Stem Cells 
Prashanth Asuri1–3, Melissa A Bartel1–3, Tandis Vazin1–3, Jae-Hyung Jang1–4, Tiffany B Wong5 and  
David V Schaffer1–3
1Department of Chemical and Biomolecular Engineering, University of California, Berkeley, California, USA; 2Department of Bioengineering,  
University of California, Berkeley, California, USA; 3The Helen Wills Neuroscience Institute, University of California, Berkeley, California, USA;  
4Department of Chemical and Biomolecular Engineering, Yonsei University, Seoul, Korea; 5Department of Molecular and Cell Biology,  
University of California, Berkeley, California, USA
330 www.moleculartherapy.org  vol. 20 no. 2 feb. 2012 
© The American Society of Gene & Cell Therapy
AAV for Enhanced Gene Delivery and Targeting
415 original cells), as compared to less than 1 targeted cell per 106 
original cells in the absence of the ZFNs.13 More recently, a new 
approach has been described to engineer DNA-binding specifici-
ties based on transcription activator–like effector (TALE) proteins 
from Xanthomonas plant pathogens and artificial restriction 
enzymes generated by fusing TALEs to the catalytic domain of 
FokI was used to generate discrete edits or small deletions within 
endogenous human genes at efficiencies of up to 25%.16 However, 
while the utilization of ZFNs and transcription activator–like 
effector nucleases (TALENs) to enhance gene-targeting efficien-
cies in hPSCs is highly promising, the approach entails custom 
engineering of a new nuclease for each new target locus, which 
requires labor, time, and resources.
Adeno-associated virus (AAV) is a nonpathogenic, nonenvel-
oped virus containing a 4.7 kb single-stranded DNA genome that 
encodes the structural proteins of the viral capsid (encoded by the 
cap gene) and the nonstructural proteins necessary for viral rep-
lication and assembly (encoded by the rep gene), flanked by short 
inverted terminal repeats.17 Recombinant versions of AAV can 
be created by inserting a sequence of interest in place of rep and 
cap, and the resulting recombinant vectors can efficiently deliver a 
transgene and safely mediate long-term gene expression in divid-
ing and nondividing cells of numerous tissues.17 Such AAV-based 
vectors have proven safe, efficient, and recently very effective for 
clinical application.18,19
An interesting property of AAV is that, as demonstrated 
by Russell and colleagues, AAV vector genomes carrying gene-
 targeting constructs can mediate HR with target loci in a cel-
lular genome at efficiencies 103–104-fold higher than plasmid 
constructs.3 The AAV genome’s inverted terminal repeats, which 
apparently mediate its entry into the RAD51/RAD54 component 
of the cellular HR pathway, play a central role in this property.20 
AAV-mediated gene targeting has been successfully applied to cells 
that AAV can effectively transduce, but naturally occurring AAV 
variants are typically inefficient at infecting a number of stem cell 
types, particularly human embryonioc stem cells (hESCs).21,22
We have implemented directed evolution—a rapid, high-
throughput selection approach to create and isolate novel mutants 
from millions of genetic variants—to rapidly engineer AAV vari-
ants with desired gene delivery properties in the absence of the 
extensive mechanistic information typically required for rational 
biomolecular design. Recent work highlights the ability to apply 
directed evolution to create AAV mutants with altered receptor 
binding, neutralizing antibody-evasion properties, and altered cell 
tropism in vitro and in vivo.23–29 Likewise, we have recently demon-
strated that directed evolution can yield novel AAV variants that 
enhance gene delivery and gene targeting in neural stem cells.21 
Here, we implement this approach to create new AAV mutants 
with the enhanced capacity to infect and, subsequently, increase 
the efficiency of AAV-mediated gene targeting in hPSCs, both 
in the presence and absence of ZFN-mediated double-stranded 
DNA breaks.
results
evaluation of wild-type serotypes
There are numerous naturally occurring AAV variants and 
serotypes, each of which has different protein capsids and thus 
somewhat different gene delivery properties for various cell types 
and tissues.30 AAV serotypes 1–6 and 8 were tested to assess their 
potential for hESC gene delivery. Initially, HSF-6 hESCs were 
infected with AAV vectors carrying green fluorescent protein 
(GFP) complementary DNA at a multiplicity of infection (MOI) 
of 10,000, and 48 hours postinfection, flow cytometry was used to 
determine the percentage of cells that express GFP and were thus 
infected by AAV. The most efficient was AAV6 (Figure 1); how-
ever, its low delivery efficiency (14.75 ± 3.08% GFP positive cells) 
places significant limitations on the fraction of cells that express a 
transgene or could undergo gene targeting. These results are con-
sistent with earlier reports showing that natural AAV serotypes 
are typically inefficient in gene delivery to human stem cells,31,32 
thus demonstrating the need to find, or evolve, an AAV variant 
capable of more efficient transduction.
AAV library generation and selection through 
directed evolution
The AAV capsid proteins, encoded by the cap gene, determine the 
virus’ ability to infect cells through their initial binding to vari-
ous cell-surface receptors, intracellular trafficking, and entry into 
the nucleus. Directed evolution is a high-throughout approach 
that involves the creation and functional selection of libraries of 
genetic mutants to isolate novel variants with desirable proper-
ties. We implemented a directed evolution strategy to create AAV 
variants capable of mediating efficient gene delivery to hESCs 
(Figure 2a). Briefly, hESCs were infected with pools of virus 
variants created using several different techniques: a library in 
which AAV2 and AAV6 cap were subjected to error-prone PCR, 
a “shuffled” library composed of random cap chimeras of seven 
parent AAV serotypes,24 an AAV2 cap library with random 7-mer 
inserts,33 and AAV2 cap with substituted loop regions.25 Following 
infection with AAV libraries (Figure 2a, step 4) and amplifica-
tion of the infectious AAV variants through adenovirus super-
infection—as AAV requires a helper virus such as adenovirus to 
induce replication—(step 5), the resulting titre of AAV rescued 
from each library condition was quantified and compared to titres 
of recovered wild-type AAV2 as a metric for relative success of 
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Figure 1 Gene expression in hescs mediated by various AAV sero-
types. HSF-6 cells were infected with numerous natural AAV serotypes at 
a MOI of 10,000. Transduction efficiency was assessed as the percentage 
of GFP positive cells measured by flow cytometry 48 hours postinfection. 
Error bars indicate standard deviation (n = 3). AAV, adeno-associated 
virus; GFP, green fluorescent protein; hESC, human embryonic stem cell; 
MOI, multiplicity of infection.
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the selection. For each selection step, viral pools from the library 
produced higher viral titres than wild-type AAV2 at MOIs of both 
10 and 100 (data not shown). These viral pools were then used as 
the starting point for the subsequent selection step (step 6). After 
three such selection steps, the successful viral cap genes were iso-
lated (step 7) and tested individually to identify variants with the 
most efficient gene delivery. In addition, the cap genes isolated 
after the third selection step were subjected to an additional round 
of evolution, i.e., additional mutagenesis (step 8) and three selec-
tion steps, to further increase the fitness of the pool.
Increased transduction efficiency of the novel 
evolved AAV variant in hescs
Nine cap variants from each library isolated after the third selection 
step of the first round of evolution were fully sequenced, and the 
AAV capsid protein variations and the frequency with which each 
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Figure 2 directed evolution of AAV and hPsc transduction by AAV 1.9. (a) Schematic representation of directed evolution. 1) A viral library 
is created by mutating the cap gene. 2) Viruses are packaged in HEK293T cells using plasmid transfection, such that each particle is composed of 
mutant capsid surrounding the cap gene encoding that protein capsid. 3) Viruses are harvested from 293 cells and purified. 4) The viral library is 
introduced to the HSF-6 hESCs in vitro. 5) Successful viruses are amplified and recovered using adenovirus rescue. 6) Successful clones are enriched 
through repeated selections. 7) Isolated viral DNA reveals selected cap genes. 8) Selected cap genes are mutated again to serve as a new starting 
point for selection. (b) Molecular model of the full AAV2 capsid, based on the solved structure,51 shows the location of the R459G mutation (blue) on 
the surface of the capsid (VP3 region), near the threefold axis of symmetry and residues known to be important for heparin and FGF receptor bind-
ing (pink). (c) AAV-mediated gene expression in hESCs. HSF-6 cells were infected with selected mutants at a MOI of 10,000. Transgene expression 
was assessed as the percentage of GFP positive cells measured by flow cytometry 48 hours postinfection. Error bars indicate the standard deviation 
(n = 3), *P < 0.01. (d) Elevating the MOI increases transduction. HSF-6 cells were infected with AAV1.9 at MOIs of 1,000, 10,000, and 100,000. 
Transgene expression was assessed as the percentage of GFP positive cells measured by flow cytometery 48 hours postinfection. Error bars indicate 
standard deviation (n = 3), *P < 0.01. (e) AAV1.9-mediated gene expression in hPSCs. HSF-6 hESCs, human dermal fibroblast-derived hiPSCs, human 
MSC-derived hiPSCs, and H1 hESCs were infected at a MOI of 10,000. Transgene expression was assessed as the percentage of GFP positive cells 
measured by flow cytometry 48 hours postinfection. Error bars indicate the standard deviation (n = 3), *P < 0.01. (f) In vitro analysis of AAV1.9 
tropism. Variant AAV1.9 (white), selected on hESCs, is less infectious on AAV-permissive cell types (HEK293T, CHO) than recombinant AAV2 (black) 
and AAV6 (gray), but more infectious on HSF-6 hESCs. Error bars indicate standard deviation (n = 3), *P < 0.01. (g) HSF-6 cells infected by AAV1.9 
maintain pluripotency marker expression. HSF-6 cells infected with AAV1.9 encoding GFP at an MOI of 100,000 were fixed and immunostained 
1 week after infection for the presence of GFP (green) and the pluripotency marker Nanog (red). AAV, adeno-associated virus; FGF, fibroblast growth 
factor; GFP, green fluorescent protein; hESC, human embryonic stem cell; hiPSC, human induced pluripotent stem cell; MOI, multiplicity of infection; 
MSC, mesenchymal stem cell.
332 www.moleculartherapy.org  vol. 20 no. 2 feb. 2012 
© The American Society of Gene & Cell Therapy
AAV for Enhanced Gene Delivery and Targeting
clone was detected in the error-prone PCR-mutagenized AAV2 
and AAV6 library are shown in Table 1. The cap genes of these 
variants were also used to package recombinant AAV carrying 
the GFP gene, under the control of the cytomegalovirus (CMV) 
promoter. These recombinant AAV variants were then used to 
infect hESCs, and the gene delivery efficiency of each virus was 
measured via flow cytometry. Of the mutants isolated from the 
error-prone PCR-mutagenized AAV2 and AAV6 library, the vari-
ant AAV EP 1.9 (or AAV1.9), which carries a single-point muta-
tion (R459G) (Figure 2b), showed the highest infection efficiency 
at 28.25 ± 1.68% GFP positive cells, representing an approximately 
threefold increase over AAV2 (its parental serotype) and a two-
fold increase over AAV6 (the best serotype) at an MOI of 10,000 
(Figure 2c). Variants isolated from the shuffled, 7-mer insertion, 
and substituted loop region libraries were sequenced and analyzed 
as well. Variants from these libraries showed increased infection 
efficiency compared to AAV2, but not AAV6 (data not shown). At 
an MOI of 100,000, the variant AAV1.9 achieved a strong infec-
tion efficiency of 48.21 ± 12.92% GFP positive cells (Figure 2d). 
It should be noted that hESCs grow as colonies that are typically 
multilayered, making accessing and infecting all of the cells in a 
colony difficult. However, AAV1.9 provides an increase in gene 
delivery efficiency, by an increase in the number of cells infected 
(Figure 2c), an increase in the relative fluorescence intensity 
of infected cells (approximately threefold higher than AAV6), 
and a significantly increased number of donor DNA molecules 
delivered to each cell (Supplementary Materials and Methods 
and Supplementary Figure S1). Interestingly, sequencing of cap 
variants isolated after an additional round of mutagenesis to the 
cap library and three additional selection steps all matched the 
sequence of AAV1.9 (data not shown).
AAV1.9 was isolated through multiple rounds of selection 
using the HSF-6 hESC line; however, the increase in gene deliv-
ery efficiency also extended to the broadly utilized H1 hESC line, 
as well as induced pluripotent cell lines including mesenchymal 
stem cell (MSC)-derived, and dermal fibroblast-derived hiPSC 
lines (Figure 2e).34 In addition, while AAV1.9 is capable of higher 
gene delivery efficiency to hESCs and hiPSCs, it is less infectious 
towards several cell types typically permissive to AAV infec-
tion (Figure 2f), indicating that in this case directed evolution 
yielded a variant that efficiently and somewhat selectively trans-
duces an ordinarily nonpermissive cell. Furthermore, the hESCs 
maintained pluripotency marker expression following infection, 
assessed via Nanog immunostaining (Figure 2g).
The R459G mutation in AAV1.9 lies close to but not within 
the heparin or fibroblast growth factor (FGF) receptor binding 
domains on the AAV capsid surface (Figure 2b), though it could 
conceivably modulate binding to the cell surface. To determine 
whether the amino acid 459 mutation alters the heparin-binding 
properties of the variant, AAV2, AAV6, and AAV1.9 were ana-
lyzed using heparin column chromatography, which can  provide a 
measure of the heparin-binding affinity of AAV variants. Despite 
its mutation residing outside the reported heparin-binding 
domain,35 and despite the loss of a positively charged residue, 
AAV1.9 displays a higher affinity for heparin compared to the 
parental serotype AAV2, as indicated by the higher NaCl concen-
tration needed to elute the majority of AAV1.9 from the heparin 
column. (Figure 3a). However, in vitro transduction of CHO and 
pgsA (a mutant CHO cell line lacking surface glycosaminoglycans 
(GAGs)) cells showed that AAV1.9 had less dependence on cell-
surface heparan sulfate proteoglycans (AAV2’s primary receptor)36 
for cell transduction (Figure 3b). Furthermore, while it exhibited 
higher transduction levels, AAV1.9 bound to hESCs at levels simi-
lar to AAV2 (Figure 3c). Collectively, these data indicate that the 
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Figure 3 Mechanistic analysis of transduction by variant AAV. (a) AAV1.9 has a higher affinity for heparin than AAV2 and AAV6. The heparin affin-
ity column chromatogram of recombinant AAV2 (black), AAV6 (gray), and AAV1.9 (white) is shown, where virus was eluted from the column using 
increasing concentrations of NaCl. Virus was quantified using qPCR. (b) In vitro characterization of AAV1.9 HSPG dependence. CHO (black) and pgsA 
(white) cells were transduced to demonstrate the decrease in HSPG dependence of AAV1.9 compared to AAV2. Error bars indicate standard deviation 
(n = 3), *P < 0.01. AAV, adeno-associated virus; hESC, human embryonic stem cell, qPCR, quantitative PCR. (c) In vitro characterization of AAV1.9 
binding affinity. AAV1.9 and its parental serotype AAV2 bind hESCs to similar extents, yet AAV1.9 is capable of significantly higher transduction of 
hESCs. Error bars indicate standard deviation (n = 3), *P < 0.01.
table 1 summary of variants isolated from three rounds of selection 
against hescs
clone name Mutations Frequency
EP 1.1 S85G, R459G 3/9
EP 1.3 R459G, V600A 1/9
EP 1.5 S85G, R447S, R459G 1/9
EP 1.8 R447S, R459G 2/9
EP 1.9 R459G 2/9
Protein sequence features and the frequency of appearance during analysis are 
listed for each clone isolated from the EP AAV2/AAV6 library.
AAV, adeno-associated virus; hESC, human embryonic stem cell.
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R459G mutation may exert its effects after initial docking to the 
cell surface, though future studies will be needed to elucidate its 
mechanism of enhanced hESC infection.
enhanced gene-targeting efficiency of the novel 
evolved AAV variant in hescs
We assessed the ability of the novel variant to mediate gene tar-
geting in hPSCs. To do so, we employed a mutated GFP-based 
reporter system, previously described by Zou et al.13 Briefly, GFP 
complementary DNA containing a 35 bp insertion harboring a 
stop codon (GFP∆35) was introduced into HSF-6 hESCs using a 
lentiviral vector (see Materials and Methods and Figure 4a). The 
donor construct (t37GFP) consisted of a promoter-less, nonfunc-
tional GFP with a 37 bp 5′ truncation, as well as 290 nucleotides 
of homology upstream and 1,619 nucleotides downstream of the 
35 bp insertion in GFP∆35. The donor plasmid was packaged 
into recombinant AAV vectors (AAV2, AAV6, and AAV1.9), and 
a hESC line carrying the mutated GFP was infected with these 
gene-targeting constructs to test their capacity to mediate gene 
correction and thereby restore GFP fluorescence. The levels of 
gene correction achieved using recombinant AAV2 and AAV6 
were below the limits of detection of flow cytometry in this assay 
(Figure 4b), whereas the variant AAV1.9 was capable of tar-
geted gene correction resulting in fluorescent hESCs (0.12%). 
Furthermore, consistent with previous reports,3 we also show that 
at similar efficiencies of gene delivery, AAV vectors can medi-
ate targeted gene correction at rates much higher than plasmid 
constructs (Figure 4b). Moreover, as discussed earlier, AAV1.9 is 
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Figure 4 AAV1.9-mediated correction of a nonfunctional GFP expressed in hescs. (a) Schematic overview depicting the targeting strategy for 
the GFP gene correction. The defective GFP gene—GFP∆35, mutated by the insertion of a 35 bp fragment containing a translational stop codon13—
was integrated into HSF-6 cells using a lentiviral vector. A targeting vector (t37GFP) containing a 5′ truncated GFP coding sequence was packaged 
into a recombinant AAV vector lacking a promoter. Homologous recombination between donor vector and integrated defective GFP∆35 gene would 
correct the 35 bp mutation and result in fluorescent hESCs. (b) Gene targeting frequencies assessed as the percentage of GFP positive cells mea-
sured via flow cytometry 72 hours postinfection. Error bars indicate standard deviation (n = 3), *P < 0.01. ND, not detectable by flow cytometry. 
(c,d) Representative analyses of the targeted correction of GFP∆35 gene. Genomic DNA from the “corrected” and “uncorrected” HSF-6 cells was 
amplified using PCR. The 35 bp mutation within the GFP∆35 gene contains an Xho I site, and therefore only the PCR products from the “uncorrected” 
cells (sample 2) can be digested using Xho I, whereas the PCR products from the corrected cells (sample 1) show the restoration of the functional GFP 
gene without the Xho I site. DNA sequencing analysis also shows AAV1.9-mediated correction of the 35 bp mutation in HSF-6 cells originally express-
ing the mutated GFP∆35 gene. (e) Time course of AAV-mediated GFP∆35 correction in HSF-6 cells. Error bars indicate standard deviation (n = 3). 
(f) Maintenance of an undifferentiated state of gene-corrected, GFP-expressing cells for 30 days postinfection. GFP positive HSF-6 cells, isolated via 
FACS, were cultured for 30 days, then fixed and probed for the presence of GFP (green), Oct4 (red), and DAPI (blue). (g) Pluripotency of the HSF-6 
cells carrying the corrected GFP gene was further confirmed through embryoid body-mediated in vitro differentiation to generate derivatives of all 
three germ layers, as indicated by the expression of the ectodermal marker β-III tubulin, the mesodermal marker α-smooth muscle actin (α-SMA), 
and the endodermal marker hepatocyte nuclear factor 3 β (HNF3β) after 24 days of differentiation (Bar = 100 μm). AAV, adeno-associated virus; CMV, 
cytomegalovirus; DAPI, 4′,6-diamidino-2-phenylindole; FACS, fluorescent-activated cell sorting; GFP, green fluorescent protein; hESC, human embry-
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also capable of higher gene delivery efficiency to H1 hESCs, and 
MSC- and dermal fibroblast-derived hiPSCs (Figure 2e), and we 
observe a corresponding increase in gene-targeting efficiencies 
(0.06–0.12%) for these cell lines as well (Table 2).
Introduction of dsBs via ZFns improves the  
gene-targeting efficiencies of AAV vectors
Directed evolution thus created a novel AAV variant that medi-
ates high levels of gene targeting in hESCs and hiPSCs, and previ-
ous reports indicate that in addition to enhancing the ability of 
the donor DNA to mediate HR, complementary approaches such 
as inducing local DSBs at the target locus can further enhance 
gene targeting.37 Recent years have witnessed the development 
of engineered restriction enzymes generated by fusing a DNA 
cleavage domain either to a zinc finger or a TAL effector DNA-
binding domain as a general approach to generate site-specific 
double-stranded chromosomal breaks and thereby greatly stim-
ulate homology-directed gene repair in a number of human cell 
lines.10–13,16 These findings provided rationale to explore whether 
stimulation of gene targeting by nuclease-mediated DSBs can be 
combined with an evolved AAV to further enhance gene target-
ing in hPSCs. We first generated AAV vectors that expressed the 
ZFNs from a CMV promoter to target a site 12 bp upstream of the 
35 bp insertion in the GFP gene (Figure 4a).38 hPSCs harboring 
the mutant GFP were infected with the two AAV vectors encoding 
a GFP-specific ZFN, as well as the AAV donor vector (t37GFP), 
and the gene-targeting efficiency was measured via flow cytom-
etry to detect cells expressing the corrected GFP. In the presence 
of a local DSB-mediated by ZFNs, we observe a fivefold to 13-fold 
increase in AAV1.9-mediated gene-targeting rates (Figure 4b and 
Table 2), from an already relatively high efficiency of 0.06–0.12% 
to 1.2–1.6% across multiple hPSC lines. Also, while not as high 
as with AAV1.9, using other AAV serotypes to deliver the donor 
construct and ZFNs did yield measurable gene correction in all 
cases, indicating the generality of using AAV to deliver both 
donor and nuclease for enhanced HR (Figure 4b and Table 2). 
Finally, we observed similar increases in gene-targeting efficien-
cies when we infected human pluripotent embryonic carcinoma 
cells (NT2) and human embryonic kidney (HEK293T) cells har-
boring the mutant GFP with AAV2 vectors encoding the GFP-
specific ZFN and the donor t37GFP plasmids, indicating the 
general utility of combining an AAV donor with DSBs at the target 
locus (Supplementary Figure S2).
To verify correction of the GFP∆35 sequence, genomic DNA 
from “corrected” (GFP positive cells isolated using fluorescence-
activated cell sorting) and “uncorrected” HSF-6 hESCs was sub-
jected to PCR to amplify the GFP sequence. The 35 bp insert of 
the mutated GFP cell line harbors a unique Xho I site that enabled 
the confirmation of GFP correction by restriction digest analysis 
(Figure 4c). Also, direct sequencing of the PCR fragments con-
firmed the correction of the mutated GFP∆35 gene (Figure 4d). 
Furthermore, the GFP positive hESCs, purified via fluorescence-
activated cell sorting, were expanded and monitored by flow cytom-
etry for 30 days, and >95% of cells maintained GFP expression 
(Figure 4e). These cells also maintained a pluripotent state during 
long-term culture following targeted gene correction as indicated 
by the expression of the pluripotency marker Oct4 (Figure 4f) and 
their ability to differentiate into cells originating from the three 
germ layers via embryoid body formation in vitro (Figure 4g).
Finally, in addition to measuring targeted gene correction via 
HR, we also assessed the frequency of random chromosomal inte-
gration of AAV1.9 vectors. HSF-6 hESCs harboring GFP∆35 were 
infected with AAV1.9 donor constructs and cultured for 14 days. 
The genomic DNA from the infected cells was subjected to PCR 
to specifically amplify a 822 bp fragment that partially spanned 
the AAV viral genome following the puromycin resistance gene 
(Supplementary Figure S3a), a region that should not participate 
in homologous recombination (Figure 4a) and would thus rep-
resent residual AAV sequence. This assay was calibrated by con-
ducting PCR in parallel on naive hESC DNA samples spiked with 
different amounts of AAV1.9 donor plasmid, ranging from 1 copy 
of AAV plasmid per 400 cellular genome copies to 1 copy of AAV 
plasmid per 20 cellular genome copies. Based on the quantifica-
tion of the samples and the standards, ~1 copy of AAV1.9 genome 
was present per 100 cells that were originally exposed to the vec-
tor (Supplementary Materials and Methods and Supplementary 
Figure S3b), consistent with earlier reports that demonstrate low 
risk of random genomic integration of AAV in human cells.37,39 To 
determine whether introduction of site-specific DSBs using ZFNs 
increases this low frequency of random integration, we coinfected 
hESCs carrying the mutant GFP with AAV1.9 vectors encoding 
the donor plasmid, as well as the GFP-specific ZFNs. We did not 
observe a significant increase in the levels of random integration 
in the presence of ZFNs (Supplementary Figure S3), which sug-
gests that at least in this system the introduction of site-specific 
DSBs may not have a strong effect on nonhomologous integration 
frequencies of AAV vectors.37,39
dIscussIon
AAV has attracted increasing attention for its ability to safely and 
efficiently mediate gene targeting in a variety of cell types.3,30,32 
However, prior studies have indicated that naturally occurring 
AAV serotypes are typically inefficient in transducing numer-
ous classes of stem cells, which can limit also the application of 
AAV-mediated gene targeting to hPSCs. Recently, two studies 
have reported the natural serotype AAV3 as the most efficient 
serotype for human pluripotent lines.31,40 In the hESC and hiPSC 
cell lines we examined, we did not observe a higher efficiency for 
table 2 summary of gene targeting experiments and rates in various 
human pluripotent lines in the presence and absence of ZFn-mediated 
dsBs
Human  
pluripotent  
cell line
% Gene targeting  
without ZFns
% Gene targeting  
with ZFns
AAV2 AAV1.9 AAV2 AAV1.9
HSF-6 hESCs ND 0.08 ± 0.02* 0.09 ± 0.04 1.2 ± 0.28*
H1 hESCs 0.02 ± 0.01 0.12 ± 0.03* 0.31 ± 0.07 1.6 ± 0.19*
MSC-iPSCs ND 0.06 ± 0.01* 0.12 ± 0.04 1.3 ± 0.14*
hFib2-iPSCs ND 0.06 ± 0.02* 0.16 ± 0.03 1.2 ± 0.19*
Values reported as mean ± SD (n = 3).
AAV, adeno-associated virus; hESC, human embryonic stem cell; iPSC, induced 
pluripotent stem cell; MSC, mesenchymal stem cell; ND, not detectable; ZFN, 
zinc finger nuclease.
*P < 0.01.
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AAV3 relative to other serotypes (Figure 2c and data not shown). 
Moreover, the reported transduction efficiency for AAV3 in the 
earlier studies was lower than 25% at a MOI of 200,000, and likely 
as a result, the maximum reported gene-targeting frequency was 
1.3 × 10−5.31 Collectively, these results indicate that different natural 
serotypes may be suited for different hPSC lines, but importantly 
that gene-targeting efforts in general may benefit from increasing 
AAV’s delivery efficiency to hPSCs.
Directed evolution has proven to be a powerful approach to 
create AAV vectors with novel capabilities, and we successfully 
demonstrate that under appropriate selective pressures AAV can 
evolve for improved transduction efficiencies in human pluripotent 
stem cells. Specifically, we isolated a new AAV variant, AAV1.9, 
that exhibited an enhanced infection efficiency of ~48% at a MOI 
of 100,000. AAV1.9 harbors a single R459G mutation that lies in 
close proximity to both the heparin and FGF receptor binding 
domains of AAV2. This variant displayed a slightly higher affinity 
for heparin compared to AAV2 (Figure 3a), though we observed 
similar levels of AAV1.9 and AAV2 binding to hESCs (Figure 3c). 
In their investigation of AAV2’s heparin-binding domain, Opie 
et al. found that a R459A AAV2 mutant was incapable of infecting 
HeLa cells, despite heparin-binding levels essentially the same as 
AAV2.41 The authors hypothesized that the R459A mutation may 
result in a defect in a later stage of viral infection.41 This finding, 
in conjunction with our observations that similar percentages of 
AAV2 and AAV1.9 bind to hESCs, suggests that the R459G muta-
tion may increase hESC gene delivery by modulating viral infec-
tion at a point following initial cell-surface docking, for example 
AAV structural rearrangement during heparan sulfate binding,42 
subsequent binding to secondary receptors, or cellular entry. 
Further studies are needed to elucidate such mechanisms.
An AAV variant with enhanced gene delivery to hESCs can 
serve as a valuable tool for numerous applications. For example, 
AAV could mediate the controlled overexpression of regulatory pro-
teins, short hairpin RNAs, or microRNAs, which would enable basic 
investigations of the roles of key factors in stem cell self-renewal or 
lineage commitment, as well as therapeutic applications that rely 
on the efficient generation of specific cell lineages. AAV has the 
potential to remain episomal and thereby mediate transient expres-
sion of such factors, compared to typically constitutive expression 
from lentiviral vectors, which may in some cases be advantageous. 
Furthermore, increased gene delivery efficiencies afford the oppor-
tunity to deliver multiple cargos effectively. For example, a twofold 
increase in the delivery of one AAV vector would translate to an 
eightfold increase in the number of cells that would be transduced 
with three vectors carrying three different transgenes (such as the 
gene-targeting construct and two ZFN-encoding vectors utilized in 
this study). Another consequence of generating AAV variants with 
higher transduction efficiencies in stem cells is the corresponding 
increase in gene-targeting efficiencies. When AAV1.9 was used 
to mediate gene correction in HSF-6 hESCs, we observed gene- 
targeting frequencies of 8 × 10−4, approximately tenfold higher than 
the reported targeting frequencies mediated by naturally occurring 
AAV serotypes.31,32 We have also observed that AAV1.9 allows for 
increased gene delivery and gene-targeting efficiencies to the H1 
hESC line, as well as dermal fibroblast- and MSC-derived iPSCs, 
thus establishing the generality of the method.
It was previously shown that AAV gene targeting could be 
enhanced with a double-stranded DNA break introduced at the 
target locus by the nuclease I-SceI,37,39 and our results build upon 
this important prior work to show for the first time that AAV can 
function effectively in conjunction with ZFNs, which can now be 
engineered for genomic site specificity.10,12,13 In addition to ZFNs, 
TALE truncation variants have recently been linked to the catalytic 
domain of Fok I to yield a new class of nucleases that can generate 
discrete edits or small deletions within endogenous human genes 
and induce gene modification in human cells by both nonhomol-
ogous end joining and HR.16 Alternatively, the DNA recognition 
properties of homing endonucleases can be re-engineered to yield 
enzymes that recognize endogenous genes in human cells.43 Such 
custom nucleases can be beneficial, as prior studies indicate that 
gene-targeting frequencies vary from locus to locus and are lower 
at nonexpressed genes,12,44 and the targeting efficiencies in this 
study may have benefitted from the use of a lentiviral vector—
which preferentially integrates into active transcription units45—as 
the target locus. Furthermore, researchers have observed that gene 
correction, gene knock-in, and knock-out vectors exhibit varying 
targeting frequencies.46,47 However, depending on the application, 
it is important to note that an appropriate AAV has the potential 
to mediate gene targeting at a given locus at rates that are suf-
ficiently high to obviate the time, labor, and resources entailed in 
generating a custom nuclease. Furthermore, as ZFNs and other 
nucleases have the potential to exhibit off-target cleavage,48,49 the 
use of effective donor DNA in the absence of DSBs offers certain 
advantages.
In conclusion, we have used directed evolution to create a 
novel AAV variant with a single-point mutation that exhibited 
enhanced gene delivery efficiency, and subsequently gene target-
ing, in hPSCs. In addition, this work demonstrates that AAV-
mediated gene-targeting frequencies can be further enhanced in 
the presence of targeted DSBs generated by the AAV vector co- 
delivery of ZFNs. These findings suggest that AAV vectors may 
find strong utility in investigations of stem cell biology and ther-
apy, ranging from the generation of reporter cell lines to therapeu-
tic gene correction.
MAterIAls And MetHods
Cell lines. Cell lines were cultured at 37 °C and 5% CO2 and, unless oth-
erwise mentioned, were obtained from the American Type Culture 
Collection (Manassas, VA). HEK293T and NT2 cells were cultured 
in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal 
bovine serum (Gibco, Carlsbad, CA) and 1% penicillin/streptomycin 
(Invitrogen, Carlsbad, CA). CHO K1 and CHO pgsA cells were cultured 
in F-12K medium (ATCC) supplemented with 10% fetal bovine serum 
(Gibco) and 1% penicillin/streptomycin (Invitrogen). HSF-6 hESCs (UC 
San Francisco) were cultured on Matrigel-coated cell culture plates (BD, 
Franklin Lakes, NJ) in X-Vivo medium (Lonza, Norwalk, CT) supple-
mented with 80 ng/ml FGF-2 (PeproTech, Rocky Hill, NJ) and 0.5 ng/ml 
TGF-β1 (R&D Systems, Minneapolis,  MN). H1 hESCs (WiCell, Madison, 
WI) and dermal fibroblast- and MSC-derived iPS cells (a kind gift from 
George Q. Daley, Children’s Hospital Boston, Boston, MA) were cul-
tured on Matrigel-coated cell culture plates (BD) in mTeSR1 maintenance 
medium (Stem Cell Technologies, Seattle, WA).
Library generation and viral production. Four replication-competent viral 
libraries were used as starting materials for selections on HSF-6 hESCs. 
336 www.moleculartherapy.org  vol. 20 no. 2 feb. 2012 
© The American Society of Gene & Cell Therapy
AAV for Enhanced Gene Delivery and Targeting
A random mutagenesis library was generated by subjecting cap genes 
from AAV2 and AAV6 to error-prone PCR using 5′-CATGGGAAA 
GGTGCCAGACG-3′ and 5′-ACCATCGGCAGCCATACCTG-3′ as 
forward and reverse primers, respectively, as previously described (EP 
Library).23 Libraries consisting of AAV2 containing random 7-mer pep-
tide inserts33 and AAV2 containing randomized cap loop regions25 were 
also utilized. Finally, a library containing shuffled DNA from the wild-
type AAV1, AAV2, AAV4, AAV5, AAV6, AAV8, AAV9 cap genes was 
packaged.24 Libraries were pooled for the selection steps. Following evolu-
tion, to create recombinant versions of selected viruses, the cap genes were 
inserted into the pXX2 recombinant AAV packaging plasmid using Not I 
and Hind III.23 Both the replication-competent AAV library and recom-
binant AAV vectors expressing GFP under the control of a CMV pro-
moter were packaged using HEK293T cells using the calcium phosphate 
transfection method, and the viruses were purified by iodixonal gradient 
centrifugation and Amicon filtration.23,27 DNase-resistant genomic titres 
were determined via quantitative PCR.23
Library selection and evolution. One selection step is defined as hESC infec-
tion using a starting library, rescue by addition of adenovirus serotype 5 (at 
levels sufficient to induce a cytopathic effect 48 hours post-adenovirus infec-
tion), and harvest of successful variants. For each selection step, cells were 
grown on Matrigel-coated plates to eliminate the use of feeder cells, which 
could become infected and bias the selection towards viral variants that trans-
duce the feeder layer. In addition, stromal cells were removed from the culture 
using collagenase digestion before the viral harvest to prevent the selection of 
viral variants that infect stromal cells instead of hESCs. One round of evolu-
tion consists of genetic diversification of the cap gene followed by three selec-
tion steps. Two rounds of evolution were performed, with clonal analysis 
(cap gene sequencing and hESC gene delivery assay for each selected virus) 
performed between each round of evolution. Following the third selection 
step, AAV cap genes were isolated from the pool of successful AAV variants 
and amplified via PCR. Cap genes were then sequenced at the University of 
California, Berkeley DNA sequencing facility and analyzed using Geneious 
software (Biomatters, Auckland, New Zealand). Three-dimensional models 
of the AAV2 capsid (Protein Databank accession number 1LP3) were ren-
dered in Pymol (DeLano Scientific, San Carlos, CA).
HPSC transduction analysis. The human pluripotent cell lines were 
plated at a density of 105 cells/well 24 hours before infection. Cells were 
infected with rAAV-GFP at an MOI of 104. Stromal cells were removed 
from the hESC and the iPSC culture using collagenase digestion before 
flow cytometry. The percentage of GFP positive cells was assessed 48 hours 
postinfection using a Beckman-Coulter Cytomics FC 500 flow cytometer 
(Beckman-Coulter, Brea, CA).
Immunofluorescence staining. Immunostaining was performed to visual-
ize the expression of pluripotency markers following AAV infection and 
gene targeting. HSF-6 hESCs were plated on a 24-well plate and infected 
as described for the transduction analysis. Forty-eight hours postinfection, 
cells were fixed in 4% paraformaldehyde for 15 minutes, washed three times 
with phosphate-buffered saline (PBS), and blocked with 1% bovine serum 
albumin (BSA) and 0.1% Triton X-100 in PBS for 30 minutes. Cells were 
incubated overnight at 4 °C with a mouse anti-Oct-3/4 primary antibody 
(1:200 dilution, Santa Cruz Biotechnology, Santa Cruz, CA) or anti-Nanog 
primary antibody (1:200 dilution, Santa Cruz Biotechnology). Cells were 
then washed three times with PBS and incubated with a secondary fluo-
rescent-conjugated Alexa Fluor 647 goat anti-mouse antibody (1:250 dilu-
tion, Invitrogen) for 2 hours, followed by 4′,6-diamidino-2-phenylindole 
(DAPI) for nuclear staining (Invitrogen) for 15 minutes. Cells were imaged 
using a Zeiss Axio Observer.A1 inverted microscope.
In vitro differentiation assay of pluripotency. Colonies of HSF-6 hESCs 
were isolated from stromal cells by collagenase enzymatic treatment and 
partially dissociated by gentle pipetting. The cells were cultivated as small 
clusters (5–10 cells) in suspension culture in ultra low-attachment plates 
(Corning, Corning, NY) to generate embryoid bodies (EBs) in X-Vivo 
medium. After 6 days, the EBs were transferred to plates precoated with 
Matrigel and further differentiated for 24 days. Immunocytochemistry as 
described above was used to investigate whether the cells express mark-
ers of the three germ layers using the following primary antibodies: ecto-
dermal: rabbit anti-β-III tubulin (1:500 dilution; Covance, Princeton, NJ); 
mesodermal: mouse anti-α-smooth muscle actin (1:500 dilution; Sigma, St 
Louis, MO); endodermal: rabbit anti-hepatocyte nuclear factor 3 β (1:500 
dilution; Millipore, Billerica, MA). Fluorescence images were acquired 
using a Nikon TE2000E2 epifluorescence microscope.
In vitro transduction and cell binding analysis. To determine the hepa-
ran sulfate dependence of AAV2 and the selected mutant, CHO K1 and 
CHO pgsA cells were plated at a density of 2.5 × 104 cells per well 24 
hours before infection. Cells were infected with AAV2-GFP, AAV6-GFP, 
or AAV1.9-GFP at MOIs ranging from 100–2,500.26 The percentage of 
GFP positive cells was assessed 48 hours postinfection using a Beckman-
Coulter Cytomics FC 500 flow cytometer.
To analyze cell-surface binding of AAV variants, cells were plated as 
described for the hESC transduction analysis. Stromal cells were removed 
from the hESC culture via collagenase digestion, and cells were incubated 
at 4 °C for 10 minutes; 105 cells were incubated with rAAV-GFP (MOI 
of 104) at 4 °C for 1 hour. Cells were washed twice with ice-cold PBS to 
remove unbound virus. DNase-resistant genomic titers were determined 
via quantitative PCR.
Heparin column chromatography. rAAV-GFP vectors were subjected to 
heparin column chromatography as previously described.23 Briefly, 1010 
vector genome containing AAV particles were loaded into a 1 ml HiTrap 
heparin column (GE Healthcare, Piscataway, NJ) previously equilibrated 
with 0.15 mol/l NaCl and 50 mmol/l Tris at pH = 7.5. Washes were per-
formed using 1 ml volumes of Tris buffer containing increasing increments 
of 50 mmol/l NaCl, starting at 150 mmol/l NaCl and ending at 750 mmol/l 
NaCl, followed by a 1 mol/l NaCl wash. Genomic titres from each fraction 
were determined via quantitative PCR.
Generation of mutant GFP hPSC lines. An internal ribosome entry site and 
puromycin resistance gene cassette (IRES-PuroR) were cloned into the Eco 
RI and Xho I sites of pFUGW (a kind gift from David Baltimore, California 
Institute of Technology, Pasadena, CA) to replace the woodchuck hepati-
tis virus post-transcriptional regulatory element (WPRE) and yield pFU-
GIP. Next, a mutant GFP sequence harboring a 35 bp insertion (GFP∆35) 
(a kind gift from Matthew H. Porteus, University of Texas Southwestern 
Medical Center, Dallas, TX) digested with Bam HI/Eco RI was inserted 
in place of the GFP sequence of similarly digested pFUGIP to construct 
pFUG∆35IP. The lentiviral vector carrying the mutated GFP was packaged 
by the calcium phosphate transient transfection method.50 Briefly, 10 µg of 
pFUG∆35IP, 5  μg of pMDL g/p PRE, 3.5 μg of pcDNA 3 IVS VSV-G, and 
1.5 μg of pRSV Rev were transfected into HEK 293T cell lines (>70% con-
fluency), which were cultured on 10 cm tissue culture plates under Iscove’s 
modified Dulbecco’s medium (IMDM) supplemented by 10% fetal bovine 
serum (FBS) and 1% penicillin/streptomycin. The lentiviral vector was har-
vested and concentrated by ultracentrifugation (L8-55M Ultracentrifuge; 
Beckman Coulter), followed by resuspension in 100 µl of PBS with 20% 
sucrose. Stable hPSC lines expressing the mutant GFP was generated by 
infection with the lentiviral vector, followed by puromycin selection (1 µg/
ml) for 1 week. GFP fluorescence was not detected in the GFP∆35 hPSCs, 
as confirmed by flow cytometry.
Gene targeting assay. The donor plasmid was generated by subcloning 
a truncated GFP gene missing the first 37 base pairs (t37GFP), inter-
nal ribosome entry site, and puromycin resistance gene cassette into 
an AAV vector plasmid (pAAV CMV GFP SN), such that the result-
ing targeting vector lacked a promoter. The ZFN expression constructs, 
driven by a CMV promoter, were generated by subcloning gene cassettes 
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containing the engineered zinc fingers targeting GFP (also a gift from 
Matthew H. Porteus) into pAAV CMV GFP SN (detailed cloning steps 
for the donor and ZFN expressing constructs available upon request). The 
donor construct and the ZFN expressing constructs were then packaged 
into the AAV2, AAV6, and AAV1.9 capsids. All viral vectors were har-
vested and purified as described earlier.
For gene-targeting experiments mediated by AAV, hPSCs were seeded 
onto 12-well tissue culture plates at a density of 105 cells/well 24 hours 
before AAV infection. The cells were infected with the AAV targeting 
vectors at an MOI of 105. For targeting experiments in the presence 
of ZFNs, the ZFN expressing vectors were added at an MOI of 105 to 
the cells in addition to the AAV targeting vectors. For gene-targeting 
experiments mediated by naked plasmid constructs, Rho kinase inhibitor 
(ROCK inhibitor, Y-27632; CalBioChem, San Diego, CA) was added to 
hPSC media 24 hours before electroporation. Cells were harvested using 
collagenase digestion, resuspended at 106 cells/ml in 100 μl Bio-Rad 
buffer (GPEB 2) containing 1 μg each of the donor plasmid and ZFN 
expression plasmids, and electroporated using the Bio-Rad Gene Pulser 
MXcell System (250 V, 500 μF, 1000 ohms; Bio-Rad, Hercules, CA). The 
cells were replated on Matrigel-coated plates in hPSC culture medium 
supplemented with ROCK inhibitor. The medium was replaced after 1 day. 
The percentage of GFP positive cells was assessed 48 hours postinfection 
using flow cytometry as described earlier.
Cell sorting and sequencing. Cells infected with AAV1.9 were cultured 
for 30 days and sorted at the UC Berkeley Cancer Center with a BD Influx 
Sorter to isolate GFP positive cells. For DNA sequencing analysis, cellular 
genomic DNA was extracted with the QIAamp DNA Micro Kit (Qiagen, 
Valencia, CA) and amplified using 5′-CCACCCTCGTGACCACCCTG-3′ 
and 5′-CGGCCATGATATAGACGTTGTGGC-3′ primers. The result-
ing PCR products were cloned using the StrataCloneTM PCR cloning kit 
(Stratagene, La Jolla, CA), and individual clones were sequenced to con-
firm the gene correction.
suPPleMentArY MAterIAl
Figure S1. AAV1.9 increases the number of donor molecules per cell.
Figure S2. AAV2-mediated correction of a nonfunctional GFP ex-
pressed in HEK293Ts and NT2s.
Figure S3. Representative analysis of residual AAV1.9 genomes.
Materials and Methods.
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